about
Attrition among human immunodeficiency virus (HIV)- infected patients initiating antiretroviral therapy in China, 2003-2010Does HAART efficacy translate to effectiveness? Evidence for a trial effectAntiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infectionPrevention of HIV-1 infection with early antiretroviral therapyEnfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South AmericaThe KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trialIllustration of a measure to combine viral suppression and viral rebound in studies of HIV therapyAge at Entry Into Care, Timing of Antiretroviral Therapy Initiation, and 10-Year Mortality Among HIV-Seropositive Adults in the United StatesThe effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trialSpatial epidemiology of recently acquired HIV infections across rural and urban areas of North CarolinaThe frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatmentCross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapyThe major genetic determinants of HIV-1 control affect HLA class I peptide presentation.Brief but efficient: acute HIV infection and the sexual transmission of HIV.Joint effects of alcohol consumption and high-risk sexual behavior on HIV seroconversion among men who have sex with menModeling clinical endpoints as a function of time of switch to second-line ART with incomplete data on switching timesThe effect of tuberculosis treatment on virologic and CD4+ cell count response to combination antiretroviral therapy: a systematic reviewAssociation between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.HIV Transmission Patterns Among Immigrant Latinos Illuminated by the Integration of Phylogenetic and Migration Data.Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infectionHigh Multiplicity Infection by HIV-1 in Men Who Have Sex with Men.Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation.The detection and management of early HIV infection: a clinical and public health emergency.HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy.Validation of Medicaid Claims-based Diagnosis of Myocardial Infarction Using an HIV Clinical CohortRisk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infectionVariability of the date of HIV diagnosis: a comparison of self-report, medical record, and HIV/AIDS surveillance data.HIV-1 viral load and phenotypic antiretroviral drug resistance assays based on reverse transcriptase activity in comparison to amplification based HIV-1 RNA and genotypic assaysCohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience.Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence.Rising prevalence of non-B HIV-1 subtypes in North Carolina and evidence for local onward transmission.African American race and HIV virological suppression: beyond disparities in clinic attendance.Effect of pulmonary tuberculosis on mortality in patients receiving HAART.Effect of early versus deferred antiretroviral therapy for HIV on survival.Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007Late presentation for human immunodeficiency virus care in the United States and Canada.Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North AmericaPotential impact of antiretroviral therapy and screening on cervical cancer mortality in HIV-positive women in sub-Saharan Africa: a simulation.Loss to clinic and five-year mortality among HIV-infected antiretroviral therapy initiators.
P50
Q21134515-646662F2-D0DF-4750-947C-C8FBB5EDFBC7Q21135313-756EA2DC-EF14-4EAB-8526-4167E0EAB236Q21142645-577CA1DF-BA10-4625-81FC-AB62D2FBCF2BQ24634688-9389F54A-A095-4511-AFA3-7598B59E033FQ28183380-375E4CE5-78F8-449D-82C7-0D782170305DQ28256092-C03BCB77-4293-4636-AF61-A2451462A46AQ28385909-9DE94A98-F289-496E-8603-22F845CB490CQ28387887-9F15DA1E-EE4C-4FFD-AEDB-E8727918858FQ28475076-9C7D5306-282A-423C-A029-8FE7B268B86BQ28539673-47BDF6B4-C8EA-4D12-87DC-D9481A974A1FQ28730788-5A3B28A0-6025-4C48-8977-1894753CBBB0Q28740329-59FA262E-DEB5-40E5-9F3F-7621CE1D6E66Q29417018-12DCFE7E-61F5-4D0D-BECA-0D840C9FEDAFQ30341429-6239FD0A-122B-4AE5-888C-EE186307909BQ30543136-AC898C19-4739-4162-B2B9-05B6A7BB6637Q30655744-AE23674C-74F9-490F-8B38-39434D8B99EAQ30658709-BB55C6F0-E94B-4DA0-BDF2-60028C00CC72Q30834094-0FDD63BE-2AF1-4DA0-9722-98EF0805390EQ30982971-45BE74BE-1882-4478-BFB0-72018E7FB559Q33479167-CC4F97FE-513E-4B8F-BC31-300062190388Q33582135-C6C16DBE-7198-4987-8B33-898B72ACCED2Q33585386-56830589-8A96-4315-9A5E-4D08B24F388BQ33586581-32FA0B88-C8C0-40FE-9825-7DE0C4B35F08Q33598231-96D61679-6682-4E75-931E-FA124FFC38BDQ33618727-25ED2DDB-341B-4F9D-96FB-338C30A33C61Q33628799-FBC7545E-FEBF-40A3-8A8D-83EC208AFA4FQ33629758-410B67B5-C0FF-46D5-988C-8298A973D4C0Q33636945-FFBF19B6-8AF5-4489-9355-FA900B92B3E5Q33648774-F4953CB0-0E8C-4BB7-9818-F3F0727A33F7Q33649563-04957225-10D5-4658-AC3C-7E1FD44EA9E2Q33696149-A9E9E653-66D8-42E6-8EA4-636030417C93Q33721474-0D909B9F-2124-4FBD-8097-932A4164B525Q33735032-9E2C3707-CABA-4CFE-A202-DE54B556D322Q33764880-D89BD655-293D-4EF5-BEDC-C2332796D894Q33789114-6B9D89B5-05E7-4AB1-AFEA-B6677D7843CCQ33814896-E56B87E0-6B91-483F-941A-B6D4CF1D8CE5Q33823556-666D463D-DF3B-4F91-9E4A-FBB24265108FQ33853922-55374C89-D98B-465A-A3C5-B42A2F4090E4Q33869309-5E7D2903-2629-47BD-B507-106285861082Q33882803-1E3B92BB-E2B5-484A-9634-518E2D3E7734
P50
description
researcher
@en
wetenschapper
@nl
name
Joseph J Eron
@en
Joseph J Eron
@nl
type
label
Joseph J Eron
@en
Joseph J Eron
@nl
prefLabel
Joseph J Eron
@en
Joseph J Eron
@nl
P31
P496
0000-0002-4938-0644